VBI Vaccines (VBIV) Shares Up 7.1%

VBI Vaccines Inc (NASDAQ:VBIV) shot up 7.1% during trading on Friday . The stock traded as high as $1.70 and last traded at $1.66. 505,203 shares were traded during trading, a decline of 45% from the average session volume of 912,663 shares. The stock had previously closed at $1.55.

Several brokerages recently commented on VBIV. ValuEngine lowered shares of VBI Vaccines from a “buy” rating to a “hold” rating in a research note on Wednesday, January 2nd. Zacks Investment Research upgraded shares of VBI Vaccines from a “sell” rating to a “hold” rating in a research note on Thursday, November 22nd. One research analyst has rated the stock with a sell rating, two have given a hold rating and two have assigned a buy rating to the stock. The company currently has an average rating of “Hold” and a consensus price target of $12.00.

The company has a current ratio of 1.61, a quick ratio of 1.55 and a debt-to-equity ratio of 0.15.

VBI Vaccines (NASDAQ:VBIV) last announced its quarterly earnings results on Friday, November 9th. The biopharmaceutical company reported ($0.24) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.22) by ($0.02). VBI Vaccines had a negative return on equity of 56.88% and a negative net margin of 6,345.29%. The company had revenue of $0.26 million for the quarter, compared to analyst estimates of $0.24 million. On average, equities analysts predict that VBI Vaccines Inc will post -0.94 earnings per share for the current year.

In other VBI Vaccines news, major shareholder Perceptive Advisors Llc acquired 14,285,714 shares of the stock in a transaction on Thursday, December 13th. The shares were bought at an average cost of $1.40 per share, with a total value of $19,999,999.60. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, Director Tomer Kariv acquired 1,428,571 shares of the stock in a transaction on Monday, December 17th. The shares were acquired at an average cost of $1.40 per share, for a total transaction of $1,999,999.40. The disclosure for this purchase can be found here. Company insiders own 16.20% of the company’s stock.

A number of institutional investors have recently modified their holdings of VBIV. Renaissance Technologies LLC purchased a new position in VBI Vaccines during the 3rd quarter worth $155,000. Alpine Global Management LLC purchased a new stake in shares of VBI Vaccines in the second quarter valued at about $222,000. Dimensional Fund Advisors LP purchased a new stake in shares of VBI Vaccines in the second quarter valued at about $223,000. Paloma Partners Management Co purchased a new stake in shares of VBI Vaccines in the second quarter valued at about $254,000. Finally, Jane Street Group LLC purchased a new stake in shares of VBI Vaccines in the second quarter valued at about $331,000. 32.45% of the stock is currently owned by institutional investors.

ILLEGAL ACTIVITY NOTICE: This report was originally posted by Chaffey Breeze and is owned by of Chaffey Breeze. If you are viewing this report on another site, it was illegally copied and republished in violation of United States and international copyright and trademark laws. The original version of this report can be viewed at https://www.chaffeybreeze.com/2019/01/11/vbi-vaccines-vbiv-shares-up-7-1.html.

VBI Vaccines Company Profile (NASDAQ:VBIV)

VBI Vaccines Inc, a biopharmaceutical company, develops and sells vaccines to address unmet needs in infectious disease and immuno-oncology in Israel and internationally. The company offers Sci-B-Vac, a third-generation hepatitis B vaccine for adults, children, and newborns; and eVLP, a vaccine platform for the design of enveloped virus-like particle vaccines that closely mimic the target virus.

Featured Story: How are institutional investors different from individual investors?

Receive News & Ratings for VBI Vaccines Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for VBI Vaccines and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply